https://scholars.lib.ntu.edu.tw/handle/123456789/581793
標題: | Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C | 作者: | SHIH-JER HSU Chiu M.-C. YU-JEN FANG Yang T.-H. Yu J.-J. CHIEH-CHANG CHEN Kuo C.-C. Lee J.-Y. CHIEN-HUNG CHEN DING-SHINN CHEN JIA-HORNG KAO |
公開日期: | 2019 | 出版社: | Elsevier B.V. | 卷: | 118 | 期: | 8 | 起(迄)頁: | 1187-1192 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background: Glecaprevir/pibrentasvir (GLE/PIB) is a pangenotypic direct-acting antiviral agent for the treatment of chronic hepatitis C virus (HCV) infection. Real-world data of GLE/PIB in Asian patients other than Japanese are limited. We thus investigated the effectiveness and safety profile of GLE/PIB in Taiwanese patients with chronic hepatitis C (CHC). Methods: CHC patients who received 8, 12, or 16 weeks of GLE/PIB between August and October of 2018 were consecutively enrolled. The treatment duration was determined according to drug label. The hepatic fibrosis was staged according to liver histology, transient elastography, fibrosis index based on 4 factors (FIB-4), or findings of ultrasonography/endoscopy. The primary endpoint was sustained virological response at week 12 off therapy (SVR12). The safety profiles were also assessed. Results: A total of 110 CHC patients with 51% of males were enrolled. The median age was 70 years. A majority (82%) of patients were infected with HCV genotype 2. Forty-six (42%) and 64 (58%) patients had advanced hepatic fibrosis and compensated cirrhosis, respectively. Forty-five (41%) non-cirrhotic patients were treated for 8 weeks. The overall SVR12 rates were 100%, regardless of baseline clinical characteristics. The common adverse events (AEs) were pruritus (12%), anorexia (6%), and fatigue (5%). Nine (8%) serious AEs unrelated to GLE/PIB occurred. Three (2%) patients had Grade 3 elevation of total bilirubin level. None had premature treatment termination, hepatic decompensation, or death. Conclusion: Interferon-free GLE/PIB regimen is highly effective and safe for Asian chronic hepatitis C patients with advanced hepatic fibrosis or compensated cirrhosis. ? 2019 Formosan Medical Association |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068205798&doi=10.1016%2fj.jfma.2019.06.014&partnerID=40&md5=3326d5e95c2d9ea32fc8bf019ae3d73c https://scholars.lib.ntu.edu.tw/handle/123456789/581793 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2019.06.014 | SDG/關鍵字: | bilirubin; glecaprevir plus pibrentasvir; ABT-493; antivirus agent; benzimidazole derivative; pibrentasvir; quinoxaline derivative; sulfonamide; abdominal infection; adult; aged; anorexia; antiviral therapy; Article; Asian; bacteremia; chronic hepatitis C; cohort analysis; compensated liver cirrhosis; controlled study; drug efficacy; drug safety; echography; fatigue; female; femur fracture; gastrointestinal hemorrhage; human; liver fibrosis; liver histology; major clinical study; male; pruritus; retrospective study; salmonellosis; side effect; sustained virologic response; Taiwanese; transient elastography; treatment duration; unspecified side effect; chronic hepatitis C; combination drug therapy; drug effect; Hepacivirus; liver cirrhosis; middle aged; pathology; Taiwan; very elderly; virology; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Taiwan |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。